Hidradenocarcinoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625) | National Cancer Institute (NCI) | 2017-09-27 |
Track Hidradenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.